Abstract
Objective
Advances in treatment of neonatal respiratory failure are responsible for a decline in the number of newborns treated with extracorporeal membrane oxygenation (ECMO). The aim of this study are to determine demographic changes, focusing on time of referral, diagnosis, and respiratory parameters in neonates put on ECMO.
Design
Retrospective review.
Setting
Tertiary ECMO center.
Patients
A total of 321 neonates were treated with ECMO from January 1987 to December 2006.
Results
Overall number of patients increased with every 5-year period, whereby congenital diaphragmatic hernia (CDH) was the most common diagnosis (53%), followed by meconium aspiration syndrome (MAS) (21%), sepsis and/or pneumonia (13%), and others such as persistent pulmonary hypertension of the newborn (PPHN), respiratory distress syndrome (RDS), or hypoplasia of the lung (13%). Worsening severity of illness as measured by ECMO duration and days on ventilator has to be stated for all diagnoses. Nevertheless, survival rate remained stable; both overall and diagnosis-specific mortality rates did not change significantly. Of all children, 67% survived to discharge or transfer, while best rates were seen for MAS (94%), followed by sepsis and/or pneumonia (69%), CDH (62%), and other diagnoses (43%). Concerning survival rate, no difference between inborn and outborn children occurred. However, between early- and late-referred children, a referral to the ECMO center during the first 24 h of life was associated with a significantly higher rate of survival (77% versus 54%, p = 0.0004), predominantly seen for CDH (67% versus 35%, p = 0.02).
Conclusion
We strongly recommend timely transfer to an ECMO center in patients with CDH who are at risk of circulatory failure.
Similar content being viewed by others
Background
ECMO is a potentially life-saving therapy for neonates suffering from severe respiratory failure. Randomized studies, especially the UK ECMO Trial, showed improved survival for neonates treated with ECMO in comparison with conventional treatment [1, 2]. First used by Bartlett et al. [3, 4] in 1975, currently more than 20,000 neonates treated with ECMO have been reported to the Extracorporeal Life Organization (ELSO), founded in 1989 [5].
Typical indications for use of ECMO are congenital diaphragmatic hernia (CDH), meconium aspiration syndrome (MAS), sepsis, pneumonia, and persistent pulmonary hypertension of the newborn (PPHN). Generally, diseases treated should be of potentially reversible character. Contraindications include gestational age <34 weeks or weight <2,000 g, coagulopathy or uncontrolled bleeding, intracranial hemorrhage exceeding grade 2, uncorrectable cardiac malformations, lethal anomalies, and irreversible brain injury [6]. Common entry criteria for neonatal ECMO according to the ELSO guidelines are listed in Table 1.
During the last 10–15 years, implementation of therapies such as surfactant, high-frequency oscillatory ventilation (HFOV), and inhaled nitric oxide (iNO) have widened therapeutic options in the treatment of critically ill neonates. As a consequence, the need for ECMO has decreased for most diagnoses, excepting CDH [7, 8]. However, improvement with HFOV and iNO is frequently only temporary, and ECMO cannot be thereby avoided. Thus, administration of those therapies may lead to delay in ECMO initiation [9, 10].
This retrospective study reports on 20 years of experience in ECMO in Mannheim, particularly on changing demographics and diagnoses as well as on the impact of additional therapies. Furthermore, it states the importance of timely transfer of children born outside an ECMO center.
Methods
Data on newborns suffering from respiratory failure who received ECMO during a 20- year period (1987–2006, divided into four 5-year periods) were collected. Four diagnostic categories were constructed: CDH, MAS, sepsis and/or pneumonia, and a mixed group (“others”). The following variables were registered: inborn/outborn, age at referral, age at ECMO initiation, use of HFOV and iNO, PaO2, PaCO2, AaDO2, oxygenation index (OI) (latest values prior to ECMO) and maximum peak inspiratory pressure (PIP) prior to ECMO, ECMO duration, days on ventilator, length of hospital stay, and survival to discharge or transfer. Referral within the first 24 h of life was classified as “early referral” and afterwards as “late referral.” Age at ECMO initiation and survival of children receiving HFOV and/or iNO prior to ECMO were compared with children who had no trial of HFOV and/or iNO. HFOV was available in Mannheim since 1981, and during the first period all transferred patients were standardized to be put on HFOV as a trial prior to ECMO. With the rising number of patients with CDH (whereby we saw that nearly all with rescue trial of HFOV were put on ECMO) this standard trial was withdrawn. iNO was available since 1992 and was applied in nearly all patients prior to ECMO since 1993.
To identify factors associated with improved survival, logistic regression analysis was performed using the following variables: diagnosis, early versus late referral, and pretreatment with HFOV and/or iNO.
Continuous variables were analyzed by using the Mann–Whitney U-test (two independent samples) and the Kruskal–Wallis test (three or more independent samples). For discrete variables, the χ 2 test was adopted, and Fisher’s exact test in absence of normal distribution. Significance level was fixed at 5%. All statistical calculations were carried out by using Statistical Analysis System (SAS) software version 8.02.
Results
During the study period, 321 newborns with respiratory failure were treated with ECMO at our institution. Mean gestational age was 38.73 weeks, and mean birth weight was 3,163 g, without relevant changes over the different periods. The number of patients increased with each 5-year period (Fig. 1). CDH was the most common diagnosis (53%), followed by MAS (21%), sepsis and/or pneumonia (13%), and “others” (13%). The distribution of diagnoses changed significantly over time. In the early periods of our study, children with CDH only represented 28% of all ECMO patients, with the percentage increasing up to 75% in period 4. Until 1999, MAS had been the most common diagnosis. In the last 5 years, also absolute numbers for MAS decreased.
Duration of ECMO increased over the study period for all diagnoses. Children with CDH had significantly longer ECMO runs (193.1 ± 70.95 h) than other children (MAS: 149.75 ± 94.94 h; sepsis/pneumonia: 153.48 ± 105.91 h; “others”: 131.97 ± 83.80 h) (p ≤ 0.0016). They also needed more days on ventilator after termination of ECMO (CDH: 25.99 ± 14.74 days; MAS: 9.21 ± 6.64 days; sepsis/pneumonia: 8.32 ± 4.63 days; “others”: 12.0 ± 10.25 days) (p < 0.0001). Time on ventilator tended to increase over the study period for all diagnoses. Length of hospital stay remained relatively stable (mean 73.8 days, range 18–445 days) (Table 2).
Values for PaO2, AaDO2, and OI prior to ECMO improved (Table 2). CDH patients showed the strongest decline in maximum PIP, while PaCO2 levels increased.
The overall survival rate was 67%, whereas best rates were seen for MAS (94%), followed by sepsis and/or pneumonia (69%), CDH (62%), and other diagnoses (43%). Both overall and diagnoses-specific mortality rates did not change significantly (Table 2).
The use of HFOV was 100% in period 1 and decreased to 61% in period 4, varying by diagnosis (CDH: 55%; MAS: 82%; sepsis/pneumonia: 90%; “others”: 57%). Children pretreated with HFOV had initiation of ECMO delayed by 34.56 h (53.52 ± 71.52 h versus 18.96 ± 21.12 h; p < 0.0001), but no difference concerning survival rate was seen (Table 3). Inhaled NO was introduced at our center in 1992, so from 1993 onwards all patients had inhaled NO trial prior to ECMO. In only 12% of these cases put on ECMO was there a temporarily response to treatment (defined as increase of paO2 levels by 15 mmHg or to above 50 mmHg). Initiation of ECMO was delayed for 37.92 h in comparison with nonresponders (75.84 ± 69.84 h versus 37.92 ± 58.56 h) (p = 0.0023), though mortality rate showed no difference (Table 3).
A total of 224 patients (70%) were transferred from other hospitals. In 137 cases, referral was performed during the first 24 h of life (early referral), and in 76 cases beyond that period (late referral). Eleven children were transported on ECMO (six of them during the first 24 h of life); they were added to neither of the two groups. The diagnostic mix between inborn and outborn children differed significantly: 89% of inborn neonates had CDH as compared with 37% of the outborn children. The percentage of inborn children increased from 10% to 47% over the last decade. A comparison between inborn and outborn children showed significantly higher PaO2 levels and lower OI for inborn children. The survival rate of inborn children did not differ from that of outborn children (Table 4).
The distribution of diagnoses in case of early referral was 42% for CDH, 38% for MAS, 13% for sepsis/pneumonia, and 7% for “other.” In contrast, the diagnoses in case of late referral were 22% for CDH, 18% MAS, 28% sepsis/pneumonia, and 32% “other” (p < 0.0001). Early referral was associated with a better survival rate: 77% of early-referred children survived, as compared with only 54% of the late-referred children (p = 0.0004). The difference could mostly be attributed to the subgroup of patients with the diagnosis CDH: the survival rate in case of early referral was 67% (39 of 58) compared with only 35% (6 of 17) in case of late referral (p = 0.02). Looking at survival rates and time of referral in other diagnoses we found a trend of better survival in early referral for sepsis/pneumonia, but this did not reach statistical significance (Table 5).
To identify factors associated with improved survival, a logistic regression model was applied. Only MAS (compared with diagnostic category “others”) showed an association with survival (odds ratio 42; p < 0.0001). The two variables of diagnostic category CDH and early/late referral only just failed to reach statistical significance, whereas pretreatment with HFOV or iNO clearly did (Table 6).
Discussion
In contrast to the international development towards decreasing need for ECMO reported by the ELSO [5, 11, 12], our center showed increasing numbers of patients due to our high degree of specialization in ECMO and focusing on CDH patients since the year 2000. During the last 5 years, over 200 CDH patients reached our center, and we put nearly 40% of these patients on ECMO.
These changes in diagnoses, except for CDH, resulted from growing use of therapies such as surfactant, HFOV, and iNO [13]. With the availability of exogenous surfactant, ECMO treatment became dispensable in many cases, especially for RDS (last treatment in our center was in 1994) and MAS [7, 14, 15]. Use of HFOV also might be responsible for decreased need for ECMO, although this has not yet been proven in a randomized controlled trial [16]. Various studies showed reduced need for ECMO contributing to iNO, except for CDH patients [8, 17–19, 20]. This might be explained by the pathophysiology of CDH: in addition to hypoplasia of the lung, structural alteration of pulmonary vessels may play an important role. The decrease in pulmonary vascular bed and medial muscular hypertrophy lead to persistent pulmonary hypertension [21–25], which is difficult to treat. According to several studies, neither surfactant therapy nor iNO were able to reduce need for ECMO in infants with CDH [18, 21, 26]. Nevertheless, HFOV and iNO may help to stabilize patients during cannulation or transfer for ECMO.
Our data show worsening severity of illness, indicated by prolonged ECMO duration and more days on ventilator. This development was seen for all diagnoses. Neonates with CDH had significantly longer ECMO runs compared with non-CDH patients, underlining their high severity of illness. Improved values for PaO2, AaDO2, and OI do not necessarily indicate healthier children, because they probably resulted from alternative treatments (surfactant, HFOV, iNO). Respiratory values may not be suitable to express severity of underlying disease. Roy et al. [12] used the same argument to explain an increase in mean PaO2/FiO2 ratio which was found by analyzing data of the ELSO registry. Changes in maximum PIP and PaCO2 can be explained by the implementation of “gentle ventilation,” which constitutes prevention of chronic lung disease by lowering maximum PIP while accepting higher PaCO2 levels [23, 27]. Lowering mean airway pressure also contributed to increased values of OI.
In spite of a tendency towards a higher percentage of children with CDH as well as higher degree of severity of illness in general, a stable survival rate was achieved. A comparison of overall survival rate between the ELSO registry and our center is limited by differences in the diagnostic mix [5]. Our center showed lower overall survival rate (67% versus 76%) but higher percentage of patients with CDH (53% versus 24%). The survival rate for CDH patients was 62% in our center in comparison with 52% reported by the ELSO [5].
Even if additional therapies contributed to fewer transfer patients and decreasing need for ECMO, especially in MAS, negative effects in cases of poor response have to be considered. Gill and colleagues hypothesized a delay of ECMO initiation caused by use of HFOV and iNO. They reported increased mortality and morbidity for neonates with MAS if ECMO initiation was postponed to more than 96 h of age [28]. Our results show a delay in ECMO initiation for almost 35 (trial of HFOV) and 38 h (iNO responder), respectively. Survival rate, however, did not differ significantly.
Analyzing the data of the ELSO, Fliman et al. [9] found a minimally increased age at cannulation when comparing the periods 1996–1999 (2.5 days) and 2000–2003 (2.7 days). Increasing age at cannulation was also reported by Hui et al. [29], who compared three periods between 1989 and 2001 in a population of 499 neonates. In accordance with our results in patients with MAS, sepsis/pneumonia, and “other,” both studies did not find an adverse effect of this late initiation on mortality rate. Two other ECMO centers did not even note increased age at cannulation [30, 31].
Awareness of the limitations of HFOV and iNO in case of severe respiratory failure is indispensable for not missing the most appropriate moment for transfer or cannulation.
The percentage of inborn children has increased over the last decade due to improvement of prenatal diagnostic skills, thus allowing early diagnosis of CDH. This opened up the possibility for a well-prepared birth in our center, and best medical care could be offered to mother and child from the very beginning. Concerning measurements of fetal lung volume by magnetic resonance imaging, Buesing et al. [32] recently reported negative selection of severely affected CDH patients in Mannheim. It is known that centralization is a factor in evidence for better survival rates in patients with CDH [33]. The ELSO recordings show a smaller increase in percentage of patients with CDH among those treated with ECMO [2, 13]. The fact that we increased our capacity from two ECMO beds in the first time period to four beds in the last period contributes to the higher number of patients treated at our center. Despite low evidence for advantages of ECMO treatment in patients with CDH [33] and an ongoing discussion about entry criteria for ECMO treatment, we have the experience that applying the classic criteria of acute hypoxemia with PaO2 below 40 mmHg can be used for fast entry in case of preductal measurement. A high amount of ductal shunting can be interpreted as a sign of severe pulmonary hypertension, especially in combination with circulatory failure. Although the mortality rate did not differ between inborn and outborn children, the higher PaO2 levels and lower OI found in inborn neonates might indicate more stable clinical condition. Based on our data, patients with CDH who qualify for ECMO treatment should be transferred to an ECMO center within the first 24 h of life. Mortality caused by late referral does not seem to be such an issue in MAS. However, also in patients with sepsis/pneumonia, the data seem to show an advantage of early transfer. A higher risk of mortality in late transfer may occur in patients with diseases such as CDH or sepsis that are more often accompanied by additional circulatory failure and resulting multi-organ dysfunction.
We suggest that the ECMO center should be contacted when best PaO2 levels only reach 50 mmHg despite use of adequate inotropic support, intensive conventional ventilation (peak pressure 30–35 mbar, oxygen 100%), or if HFOV and iNO are unable to improve pulmonary condition within 12 h (oxygenation index higher than 30).
Boedy and colleagues analyzed 158 cases of neonates referred to their ECMO program and found a hidden mortality rate of 11.3% [34]. We speculate that early referral also contributes to a lower hidden mortality rate. The management of timely but also safe transport requires specialized transport programs. Therefore, our findings should also motivate further elaboration of such programs.
The focus on neonates with CDH is a special feature of our center. In recent years, additional treatments (HFOV and iNO) have more often been used by the referring hospitals, leading to delay in ECMO initiation. Due to this development, transportation of critically ill patients on HFOV and iNO will be necessary. Early referral (<24 h) was superior to late referral in patients with CDH, and possibly in other diseases with poor response to additional treatments. It will be a future challenge to identify these patients by registering, e.g., hemodynamic parameters, as we have discussed that circulatory failure may be responsible for the higher mortality in patients transferred at a late stage.
References
UK Collaborative ECMO Trial Group (1996) UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 348:75–82
Elbourne D, Field D, Mugford M (2002) Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev, CD001340
Bartlett RH (1985) Esperanza: presidential address. Trans Am Soc Artif Intern Organs 31:723–726
Bartlett RH, Gazzaniga AB, Jefferies MR, Huxtable RF, Haiduc NJ, Fong SW (1976) Extracorporeal membrane oxygenation (ECMO): cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs 22:80–93
ECMO Registry of the Extracorporeal Life Support Organization (ELSO) (2006) Ann Arbor, Michigan
Rais-Bahrami K, Van Meurs KP (2005) ECMO for neonatal respiratory failure. Semin Perinatol 29:15–23
El Shahed AI, Dargaville P, Ohlsson A, Soll RF (2007) Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev, CD002054
Finer NN, Barrington KJ (2006) Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev, CD000399
Fliman PJ, deRegnier RA, Kinsella JP, Reynolds M, Rankin LL, Steinhorn RH (2006) Neonatal extracorporeal life support: impact of new therapies on survival. J Pediatr 148:595–599
Hintz SR, Suttner DM, Sheehan AM, Rhine WD, Van Meurs KP (2000) Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics 106:1339–1343
Kössel H, Bauer K, Kewitz G, Karaca S, Versmold H (2000) Do we need new indications for ECMO in neonates pretreated with high-frequency ventilation and/or inhaled nitric oxide? Intensive Care Med 26:1489–1495
Conrad SA, Rycus PT, Dalton H (2005) extracorporeal life support registry report 2004. ASAIO J 51:4–10
Roy BJ, Rycus P, Conrad SA, Clark RH (2000) The changing demographics of neonatal extracorporeal membrane oxygenation patients reported to the Extracorporeal Life Support Organization (ELSO) Registry. Pediatrics 106:1334–1338
Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH, Survanta in Term Infants Study Group (1998) Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 132:40–47
Soll RF (1998) Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev, CD001149
Bhuta T, Clark RH, Henderson-Smart DJ (2001) Rescue high frequency oscillatory ventilation vs conventional ventilation for infants with severe pulmonary dysfunction born at or near term. Cochrane Database Syst Rev, CD002974
The Neonatal Inhaled Nitric Oxide Study Group (1997) Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 336:597–604
The Neonatal Inhaled Nitric Oxide Study Group (NINOS) (1997) Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragma hernia. Pediatrics 99:838–845
Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM, The Inhaled Nitric Oxide Study Group (1997) Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 336:605–610
Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP, Clinical Inhaled Nitric Oxide Research Group (2000) Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 342:469–474
Farrow KN, Fliman P, Steinhorn RH (2005) The diseases treated with ECMO: focus on PPHN. Semin Perinatol 29:8–14
Cogo PE, Zimmermann LJ, Rosso F, Tormena F, Gamba P, Verlato G, Baritussio A, Carnielli VP (2002) Surfactant synthesis and kinetics in infants with congenital diaphragmatic hernia. Am J Respir Crit Care Med 166:154–158
Mohseni-Bod H, Bohn D (2007) Pulmonary hypertension in congenital diaphragmatic hernia. Semin Pediatr Surg 16:126–133
Ostrea EM, Villanueva-Uy ET, Natarajan G, Uy HG (2006) Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management. Pediatr Drugs 8:179–188
Walsh MC, Stork EK (2001) Persistent pulmonary hypertension of the newborn: rational therapy based on pathophysiology. Clin Perinatol 28:609–627
Van Meurs K, Congenital Diaphragmatic Hernia Study Group (2004) Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J Pediatr 145:312–316
Wung JT, James LS, Kilchevsky E, James E (1985) Management of infants with severe respiratory failure and persistance of the fetal circulation, without hyperventilation. Pediatrics 76:488–494
Gill BS, Neville HL, Khan AM, Cox CS, Lally KP (2002) Delayed institution of extracorporeal membrane oxygenation is associated with increased mortality rate and prolonged hospital stay. J Pediatr Surg 37:7–10
Hui TT, Danielson PD, Anderson KD, Stein JE (2002) The impact of changing neonatal respiratory management on extracorporeal membrane oxygenation utilization. J Pediatr Surg 37:703–705
Kennaugh JM, Kinsella JP, Abman SH, Hernandez JA, Moreland SG, Rosenberg AA (1997) Impact of new treatments for neonatal pulmonary hypertension on extracorporeal membrane oxygenation use and outcome. J Perinatol 17:366–369
Kugelman A, Gangitano E, Taschuk R, Garza R, Riskin A, McEvoy C, Durand M (2005) Extracorporeal membrane oxygenation in infants with meconium aspiration syndrome: a decade of experience with venovenous ECMO. J Pediatr Surg 40:1082–1089
Buesing KA, Kilian AK, Schaible T, Dinter DJ, Neff KW (2008) MR lung volume in fetal congenital diaphragmatic hernia: logistic regression analysis mortality and extracorporeal membrane oxygenation. Radiology 248:233–239
Logan JW, Rice HE, Goldberg RN, Cotton CM (2007) Congenital diaphragmatic hernia: a systematic review and summary of best-evidence practice strategies. J Perinatol 27:535–549
Boedy RF, Howell CG, Kanto WP (1990) Hidden mortality rate associated with extracorporeal membrane oxygenation. J Pediatr 117:462–464
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schaible, T., Hermle, D., Loersch, F. et al. A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center. Intensive Care Med 36, 1229–1234 (2010). https://doi.org/10.1007/s00134-010-1886-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-010-1886-5